"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Indivior Solutions","Indivior PLC","$589,000,000","$0","$589,000,000","2020","20200724","government-contracting-related offenses","False Claims Act and related","","Indivior Solutions pleaded guilty to a one-count felony information and, together with its parent companies Indivior Inc. and Indivior plc, agreed to pay a total of $600 million to resolve criminal and civil liability associated with the marketing of the opioid-addiction-treatment drug Suboxone.  Indivior Solutions pleaded guilty to a one-count felony criminal information charging false statements relating to health care matters and agreed to pay a criminal fine, forfeiture, and restitution totaling $289 million. Under the civil settlement, Indivior Inc. and Indivior plc agreed to pay a total of $300 million to resolve claims that the marketing of Suboxone caused false claims to be submitted to government health care programs. The $300 million settlement amount included approximately $209.3 million to the federal government and $90.7 million to states that opt to participate in the agreement. Indivior also agreed to pay $10 million to the Federal Trade Commission (see separate entry).","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","United Kingdom","","publicly traded","LSE: INDV","pharmaceuticals","specialty pharmaceuticals","https://www.justice.gov/opa/pr/indivior-solutions-pleads-guilty-felony-charge-and-indivior-entities-agree-pay-600-million",""
"Indivior, Inc.","Indivior PLC","$10,000,000","$0","$10,000,000","2020","20200724","competition-related offenses","price-fixing or anti-competitive practices","","Indivior, Inc. agreed to pay $10 million to settle Federal Trade Commission allegations that it violated antitrust laws through a deceptive scheme to thwart lower priced generic competition with its branded opioid replacement therapy drug Suboxone.","federal","agency action","Federal Trade Commission","civil","","","","","","","","","","","","United Kingdom","","publicly traded","LSE: INDV","pharmaceuticals","specialty pharmaceuticals","https://www.ftc.gov/news-events/press-releases/2020/07/indivior-inc-pay-10-million-consumers-settling-ftc-charges",""
"Indivior plc","Indivior PLC","$300,000,000","$0","$300,000,000","2021","20210427","healthcare-related offenses","off-label or unapproved promotion of medical products","","Indivior agreed to pay over $300 million to state governments to resolve allegations that it falsely and aggressively marketed Suboxone, resulting in improper use of state Medicaid funds. Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. ","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","United Kingdom","","publicly traded","LSE: INDV","pharmaceuticals","specialty pharmaceuticals","https://www.oag.ca.gov/news/press-releases/attorney-general-bonta-announces-300-million-settlement-against-indivior",""
